Kalshi has launched a pilot to let people bet on clinical trial and regulatory outcomes for biotech drugs, arguing public markets provide real-time probabilities that cut through corporate messaging. Researchers, ethicists and trial participants, including former FDA commissioner Robert Califf and patients, warn the idea could compromise scientific integrity and endanger participants by creating perverse incentives. The plan has also raised concerns about insider information after reports of a teleprompter operator profiting on Kalshi. The controversy sets up potential regulatory and ethical challenges for prediction markets in healthcare.
Kalshi Announces Pilot Letting People Bet On Cancer Trial Outcomes — Critics Call It Dangerous
Shutterstock / Futurism
Prediction marketplaces Kalshi and Polymarket have long attracted controversy for permitting wagers on ethically sensitive topics. Now, Kalshi says it will pilot "biotech prediction markets" that allow users to bet on whether clinical trials or regulatory decisions for promising drugs will succeed. The proposal has ignited a sharp debate among researchers, patients and ethicists.
Kalshi's Argument
Kalshi announced the pilot program last month, saying a publicly listed contract tied to a trial or regulatory outcome would provide a "continuously updated, public probability" that reflects the weight of evidence rather than the sponsor's preferred messaging. A Kalshi spokesperson told The New York Times that the markets would not undermine research integrity and could cut through hype surrounding biotech companies and their drug candidates.
Ethical And Scientific Concerns
Researchers and ethicists responded with alarm. Critics warn that active markets could distort incentives and influence behavior inside trials: if markets strongly favor failure, participants might feel pressured to withdraw, potentially compromising trial results and patient safety. "Turning loose a betting market in an ongoing randomized clinical trial really is a breach of scientific conduct," said Robert Califf, who served as FDA commissioner in the Biden administration.
"We're literally trying to stay alive. It's not a game. The introduction of gambling into the process really creates an ethical mess,"
Boston University humanities professor Joshua Pederson, writing in The Guardian, described choosing a trial for his son — who has a very aggressive tumor — as a terrifying, high-stakes decision. He said the thought that strangers could bet on whether his child's treatment succeeds or fails is "enraging," likening such markets to other ethically repugnant "death markets." Kalshi says it will not allow markets on assassination or similar topics.
Wider Context And Risks
The announcement coincided with reporting that a White House teleprompter operator made more than $100,000 on Kalshi by betting on what President Donald Trump would say, renewing concerns about insider information and market integrity. Critics argue that prediction markets tied to ongoing trials could create opportunities for misuse and would likely attract regulatory scrutiny from agencies concerned with patient safety and research ethics.
Where This Leaves Us
The debate highlights a broader question about the limits of marketized information: can open prediction markets improve transparency around scientific outcomes, or do they create perverse incentives that place vulnerable people at risk? Regulators, trial sponsors and patient advocates will likely weigh in as Kalshi proceeds with its pilot.
Help us improve.
